Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.16.6679

Somatostatin Analogues Do Not Prevent Carcinoid Crisis  

Guo, Lin-Jie (Department of Gastroenterology, West China Hospital, Sichuan University)
Tang, Cheng-Wei (Department of Gastroenterology, West China Hospital, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.16, 2014 , pp. 6679-6683 More about this Journal
Abstract
Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.
Keywords
Carcinoid crisis; neuroendocrine tumors; SSTA; prophylaxis;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Ahlman H, Ahlund L, Dahlstrom A, et al (1988a). SMS 201- 995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization. Anesth Analg, 67, 1142-8.
2 Ahlman H, Ahlund L, Dahlstrom A, et al (1987). Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. Br J Cancer, 56, 840-2.   DOI
3 Ahlman H, Ahlund L, Nilsson O, et al (1988b). Carcinoid tumour cells in long-term culture: release of serotonin but not of tachykinins on stimulation with adrenoceptor agonists. Int J Cancer, 42, 506-10.   DOI
4 Auernhammer CJ, Goke B (2011). Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut, 60, 1009-21.   DOI
5 Balestrero LM, Beaver CR, Rigas JR (2000). Hypertensive crisis following meperidine administration and chemoembolization of a carcinoid tumor. Arch Intern Med, 160, 2394-5.   DOI
6 Bissonnette RT, Gibney RG, Berry BR, et al (1990). Fatal carcinoid crisis after percutaneous fine-needle biopsy of hepatic metastasis: case report and literature review. Radiology, 174, 751-2.   DOI
7 Darby C, Sinclair M, Westaby S (1990). Treatment of a malignant bronchial carcinoid affecting the mediastinum and left atrium by radical two stage resection with cardiopulmonary bypass and somatostatin infusion. Br Heart J, 63, 55-7.   DOI
8 Davi MV, Bodei L, Francia G, et al (2006). Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest, 29, 563-7.   DOI
9 De Keizer B, Van Aken MO, Feelders RA, et al (2008). Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr 3] octreotate. Eur J Nucl Med Mol Imag, 35, 749-55.   DOI
10 de Vries H, Verschueren RC, Willemse PH, et al (2002). Diagnostic, surgical and medical aspect of the midgut carcinoids. Cancer Treat Rev, 28, 11-25.   DOI
11 Debas HT, Mulvihill SJ (1994). Neuroendocrine gut neoplasms. Important lessons from uncommon tumors. Arch Surg, 129, 965-71.   DOI
12 Erdem R, Slabbynck H, Van den Branden F (2010). Carcinoid crisis with fatal coronary spasm in a small localized peripheral bronchial carcinoid. Acta Cardiol, 65, 471-5.
13 Fujie S, Zhou W, Fann P, et al (2010). Carcinoid crisis 24 hours after bland embolization: a case report. Biosci Trends, 4, 143-4.
14 Karmy-Jones R, Vallieres E (1993). Carcinoid crisis after biopsy of a bronchial carcinoid. Ann Thorac Surg, 56, 1403-5.   DOI
15 Gillams A, Cassoni A, Conway G, et al (2005). Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging, 30, 435-41.   DOI
16 Holdcroft A (2000). Hormones and the gut. Br J Anaesth, 85, 58-68.   DOI   ScienceOn
17 Janssen M, Salm EF, Breburda CS, et al (2000). Carcinoid crisis during transesophageal echocardiography. Intensive Care Med, 26, 254.   DOI
18 Kharrat HA, Taubin H (2003). Carcinoid crisis induced by external manipulation of liver metastasis. J Clin Gastroenterol, 36, 87-8.   DOI
19 Kinney MA, Warner ME, Nagorney DM, et al (2001). Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth, 87, 447-52.   DOI
20 Koopmans KP, Brouwers AH, De Hooge MN, et al (2005). Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med, 46, 1240-3.
21 Kvols LK, Martin JK, Marsh HM, et al (1985). Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med, 313, 1229-30.
22 Kvols LK, Moertel CG, O'Connell MJ, et al (1986). Treatment of the malignant carcinoid syndrome. Evaluation of a longacting somatostatin analogue. N Engl J Med, 315, 663-6.   DOI   ScienceOn
23 Lawrence JP, Ishizuka J, Haber B, et al (1990). The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. Surgery, 108, 1131-4.
24 Marsh HM, Martin JK, Jr., Kvols LK, et al (1987). Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology, 66, 89-91.   DOI
25 Lewis MA, Jaramillo S, Roberts L, et al (2012). Hepatic artery embolization for neuroendocrine tumors: Postprocedural management and complications. Oncologist, 17, 725-31.   DOI
26 Lipshutz HG, Kolbeck K, Russel L, et al (2012). Incidence and management of carcinoid crisis during liver directed therapy for metastatic neuroendocrine tumors. J Vascular Intervent Radiology, 23, 577.
27 Majeed F, Porter TR, Tarantolo S, et al (2007). Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr, 8, 386-9.   DOI
28 Massimino K, Harrskog O, Pommier S, et al (2013). Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol, 107, 842-6.   DOI
29 McPherson A, Regan J, Jackson N (2009). The case report and palliative management of a patient with carcinoid syndrome and crises. J Palliat Med, 12, 743-5.   DOI
30 Modlin IM, Pavel M, Kidd M, et al (2010). Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther, 31, 169-88.
31 Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097.   DOI   ScienceOn
32 Morrisroe K, Sim IW, McLachlan K, et al (2012). Carcinoid crisis induced by repeated abdominal examination. Intern Med J, 42, 342-4.   DOI
33 Parris WCV, Oates JA, Kambam J, et al (1988). Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome. Canadian J Anaesthesia, 35, 413-6.   DOI
34 Oberg K, Kvols L, Caplin M, et al (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol, 15, 966-73.   DOI   ScienceOn
35 Ockert DB, White RD (1988). Anesthetic management of patients with carcinoid heart disease undergoing cardiac surgery: two case reports and a review of previous experience. J Cardiothorac Anesth, 2, 658-65.   DOI
36 Papadogias D, Makras P, Kossivakis K, et al (2007). Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. Eur J Gastroenterol Hepatol, 19, 1154-9.   DOI
37 Parry RG, Glover S, Dudley CR (1996). Acute renal failure associated with carcinoid crisis. Nephrol Dial Transplant, 11, 2489-90.   DOI
38 Pekarek Z, Skacel Z, Trefny M (1997). The treatment of lifethreatening carcinoid crisis by octreotide (Sandostatin (registered trademark)). Klinicka Onkologie, 10, 20-3.
39 Raikhelkar JK, Weiss AJ, Maysick L, et al (2012). Adjuvant therapy with methylene blue in the treatment of postoperative vasoplegic syndrome caused by carcinoid crisis after tricuspid valve replacement. J Cardiothorac Vasc Anesth, 26, 878-9.   DOI
40 Ramage JK, Ahmed A, Ardill J, et al (2012). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut, 61, 6-32.   DOI
41 Ramage JK, Davies AH, Ardill J, et al (2005). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut, 54, 1-16.
42 Sinha V, Dyer P, Shuvro RC, et al (2009). Case of carcinoid crisis following a fine-needle biopsy of hepatic metastasis. Eur J Gastroenterol Hepatol, 21, 101-3.   DOI
43 Roy RC, Carter RF, Wright PD (1987). Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity. Anaesthesia, 42, 627-32.   DOI
44 Schmid HA (2008). Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol, 286, 69-74.   DOI
45 Shah A, Panchatsharam S, Ashley E (2012). Recurrent acute severe pulmonary oedema as a presentation of carcinoid crisis following cardiac surgery. J Intensive Care Society, 13, 251-5.   DOI
46 Tomassetti P, Migliori M, Lalli S, et al (2001). Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol, 12, 95-9.
47 Turaga KK, Kvols LK (2011). Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin, 61, 113-32.   DOI
48 van Diepen S, Sobey A, Lewanczuk R, et al (2013). A case of acute respiratory distress syndrome responsive to methylene blue during a carcinoid crisis. Can J Anaesth, 60, 1085-8.   DOI
49 Wangberg B, Ahlman H, Nilsson O, et al (1990). Amine handling properties of human carcinoid tumour cells in tissue culture. Neurochem Int, 17, 331-41.   DOI
50 Wangberg B, Nilsson O, Theodorsson E, et al (1991). The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells. Br J Cancer, 64, 23-8.   DOI
51 Yao JC, Hassan M, Phan A, et al (2008). One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol, 26, 3063-72.   DOI   ScienceOn
52 Watson JT, Badner NH, Ali MJ (1990). The prophylactic use of octreotide in a patient with ovarian carcinoid and valvular heart disease. Can J Anaesth, 37, 798-800.   DOI
53 Westberg G, Ahlman H, Nilsson O, et al (1997). Secretory patterns of tryptophan metabolites in midgut carcinoid tumor cells. Neurochem Res, 22, 977-83.   DOI
54 Wu BS, Hu Y, Sun J, et al (2014). Analysis on the characteristics and prognosis of pulmonary neuroendocrine tumors. Asian Pac J Cancer Prev, 15, 2205-10.   과학기술학회마을   DOI   ScienceOn
55 Yazbek-Karam VG, Haswani RW, Mousallem NM, et al (2009). Severe intra-operative carcinoid crisis in a patient having carcinoid heart disease. Acta Anaesthesiol Scand, 53, 414-5.   DOI
56 Yucel B, Babacan NA, Kacan T, et al (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev, 14, 6687-92.   과학기술학회마을   DOI   ScienceOn
57 Zeng YJ, Liu L, Wu H, et al (2013). Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Asian Pac J Cancer Prev, 14, 5775-81.   과학기술학회마을   DOI   ScienceOn
58 Zimmer C, Kienbaum P, Wiesemes R, et al (2003). Somatostatin does not prevent serotonin release and flushing during chemoembolization of carcinoid liver metastases. Anesthesiology, 98, 1007-11.   DOI
59 Deguchi H, Deguchi K, Tsukada T, et al (1994). Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Intern Med, 33, 100-2.   DOI